Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):393–399. doi: 10.1097/QAI.0000000000000746

Table 1.

Baseline Characteristics of AHI Participants, N=36.

Median (IQR) or Total (%)
Age 28(24 – 33)
Male 32 (89%)
Bachelor’s degree or higher 21 (58%)
Days post HIV transmission 19 (15–24)
Fiebig I/II* 23 (64%)
CRF01_AE 31 (86%)
CD4 Count (cells/mm3) 411 (338–568)
CDS Count (cells/mm3) 578 (399–1013)
Plasma HIV RNA (Iog10 copies/ml) 5.52 (4.56–5.87)
CSF HIV RNA (Iog10 copies/ml) 3.37 (2.19–4.35)
No drug use** 26 (72%)
*

Fiebig I: HIV RNA+; Fiebig II: HIV RNA+, p24 antigen +.

**

Denies any lifetime drug use or any drug use in 4 months prior to enrollment